Neoadjuvant chemotherapy plus PD-1 blockade for locally advanced gastric cancer: Clinical outcomes and CD103+CD8+ T cells as a response-associated biomarker
Abstract
IntroductionProgrammed death-1 (PD-1) inhibitors combined with chemotherapy are established for advanced gastric cancer, but their role in the neoadjuvant treatment of locally advanced gastric cancer (LAGC) remains incompletely defined. Biomarkers associated with pathological response are also needed to improve patient stratification.MethodsThis retrospective cohort included 144 patients with LAGC who received neoadjuvant chemotherapy plus a PD-1 inhibitor followed by curative-intent surgery between June 2021 and December 2025. Pathological and radiographic responses, survival, surgical outcomes, and treatment-related adverse events were evaluated. Multiplex immunofluorescence was performed in paired tumor specimens from an exploratory subset of 36 sintilimab-treated patients. Multivariable logistic and Cox regression analyses were used to assess factors associated with pathological response and survival.ResultsThe pathological complete response (pCR) and major pathological response (MPR) rates were 18.0% and 36.0%, respectively, and the R0 resection rate was 95.0%. The 1-year overall survival (OS) and disease-free survival (DFS) rates were 86.9% and 77.4%, respectively. Grade 1–2 treatment-related adverse events occurred in 91.7% of patients and grade 3 events in 30.6%; no grade 4 or 5 events occurred. PD-L1 CPS ≥1 was independently associated with a higher likelihood of MPR (adjusted OR for non-MPR, 0.31; 95% CI, 0.13–0.70; P = 0.006), but was not independently associated with OS or DFS. Baseline intratumoral CD103+CD8+ T-cell density was numerically higher in responders than in non-responders, but this difference was not significant after false discovery rate correction (adjusted P = 0.0662). Paired analyses showed a greater treatment-associated increase in CD103+CD8+ T-cell density among responders, whereas no statistically significant difference in CD103-CD8+ T-cell density was observed between response groups.ConclusionIn this retrospective surgical cohort, neoadjuvant chemotherapy plus PD-1 blockade was associated with encouraging pathological response rates, a high R0 resection rate, and manageable toxicity. Higher PD-L1 expression was associated with pathological response but not survival. Exploratory paired-tissue findings suggest that treatment-associated increases in intratumoral CD103+CD8+ T-cell density may represent a response-associated immune feature requiring prospective validation.
Related
- Genomic alterations associated with response to neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
- Neoadjuvant chemotherapy in locally advanced colon cancer: lessons from the NeoCol trial and the limits of anatomical risk stratification.
- Relative change rate of neutrophil-to-albumin ratio (ΔNAR) during neoadjuvant chemotherapy predicts axillary pathological complete response in locally advanced breast cancer
- Efficacy and safety of neoadjuvant chemotherapy with toripalimab in locally advanced nasopharyngeal carcinoma: a phase II trial and biological correlate analysis
- Multimodal prediction of neoadjuvant chemotherapy response in locally advanced gastric cancer: a multicenter cohort study
BibTeX
@article{hao2026neoadjuvant,
title = {{Neoadjuvant chemotherapy plus PD-1 blockade for locally advanced gastric cancer: Clinical outcomes and CD103+CD8+ T cells as a response-associated biomarker}},
author = {Chunlin Hao and Jidong Tan and Shuai Liu and Xiaolong Zhao and Xisheng Yang and Mengbin Li and Chunsheng Xu},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1948752},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1948752},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Neoadjuvant chemotherapy plus PD-1 blockade for locally advanced gastric cancer: Clinical outcomes and CD103+CD8+ T cells as a response-associated biomarker
AU - Chunlin Hao
AU - Jidong Tan
AU - Shuai Liu
AU - Xiaolong Zhao
AU - Xisheng Yang
AU - Mengbin Li
AU - Chunsheng Xu
PY - 2026
DA - 2026/11/10
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1948752
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1948752
AB - IntroductionProgrammed death-1 (PD-1) inhibitors combined with chemotherapy are established for advanced gastric cancer, but their role in the neoadjuvant treatment of locally advanced gastric cancer (LAGC) remains incompletely defined. Biomarkers associated with pathological response are also needed to improve patient stratification.MethodsThis retrospective cohort included 144 patients with LAGC who received neoadjuvant chemotherapy plus a PD-1 inhibitor followed by curative-intent surgery between June 2021 and December 2025. Pathological and radiographic responses, survival, surgical outcomes, and treatment-related adverse events were evaluated. Multiplex immunofluorescence was performed in paired tumor specimens from an exploratory subset of 36 sintilimab-treated patients. Multivariable logistic and Cox regression analyses were used to assess factors associated with pathological response and survival.ResultsThe pathological complete response (pCR) and major pathological response (MPR) rates were 18.0% and 36.0%, respectively, and the R0 resection rate was 95.0%. The 1-year overall survival (OS) and disease-free survival (DFS) rates were 86.9% and 77.4%, respectively. Grade 1–2 treatment-related adverse events occurred in 91.7% of patients and grade 3 events in 30.6%; no grade 4 or 5 events occurred. PD-L1 CPS ≥1 was independently associated with a higher likelihood of MPR (adjusted OR for non-MPR, 0.31; 95% CI, 0.13–0.70; P = 0.006), but was not independently associated with OS or DFS. Baseline intratumoral CD103+CD8+ T-cell density was numerically higher in responders than in non-responders, but this difference was not significant after false discovery rate correction (adjusted P = 0.0662). Paired analyses showed a greater treatment-associated increase in CD103+CD8+ T-cell density among responders, whereas no statistically significant difference in CD103-CD8+ T-cell density was observed between response groups.ConclusionIn this retrospective surgical cohort, neoadjuvant chemotherapy plus PD-1 blockade was associated with encouraging pathological response rates, a high R0 resection rate, and manageable toxicity. Higher PD-L1 expression was associated with pathological response but not survival. Exploratory paired-tissue findings suggest that treatment-associated increases in intratumoral CD103+CD8+ T-cell density may represent a response-associated immune feature requiring prospective validation.
SN - 2234-943X
ER -